{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:15:22Z","timestamp":1775330122594,"version":"3.50.1"},"reference-count":297,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French National Institute of Health and Medical Research (INSERM)"},{"name":"French Research Ministry"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic CD5+\/CD19+ B lymphocytes in the blood. These cells migrate to and proliferate in the bone marrow and lymphoid tissues. Despite the development of new therapies for CLL, drug resistance and disease relapse still occur; novel treatment approaches are therefore still needed. Inhibition of the angiogenesis involved in the progression of CLL might be a relevant therapeutic strategy. The literature data indicate that vascular endothelial growth factor, angiopoietin-2, and matrix metalloproteinase-9 are pro-angiogenic factors in CLL. A number of other CLL factors might have pro-angiogenic activity: fibroblast growth factor-2, certain chemokines (such as CXCL-12 and CXCL-2), tumor necrosis factor-\u03b1, insulin-like growth factor-1, neutrophil gelatinase-associated lipocalin, and progranulin. All these molecules contribute to the survival, proliferation, and migration of CLL cells. Here, we review the literature on these factors\u2019 respective expression profiles and roles in CLL. We also summarize the main results of preclinical and clinical trials of novel agents targeting most of these molecules in a CLL setting. Through the eradication of leukemic cells and the inhibition of angiogenesis, these therapeutic approaches might alter the course of CLL.<\/jats:p>","DOI":"10.3390\/cancers17010072","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T13:37:51Z","timestamp":1735738671000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?"],"prefix":"10.3390","volume":"17","author":[{"given":"Marianne","family":"Ayoub","sequence":"first","affiliation":[{"name":"Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santos A.","family":"Susin","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-6922","authenticated-orcid":false,"given":"Brigitte","family":"Bauvois","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Sorbonne Universit\u00e9, Universit\u00e9 Paris Cit\u00e9, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F-75006 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1582-4934.2005.tb00355.x","article-title":"Matrix metalloproteinases and angiogenesis","volume":"9","author":"Rundhaug","year":"2005","journal-title":"J. Cell. Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cncr.22086","article-title":"Role of angiogenesis in chronic lymphocytic leukemia","volume":"107","author":"Letilovic","year":"2006","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.leukres.2012.05.021","article-title":"Angiogenic factors in chronic lymphocytic leukemia","volume":"36","author":"Xia","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/bjh.12344","article-title":"Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy","volume":"162","author":"Ramsay","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"key":"ref_6","first-page":"147","article-title":"Basic fibroblast growth factor overexpression in endothelial cells: An autocrine mechanism for angiogenesis and angioproliferative diseases","volume":"7","author":"Gualandris","year":"1996","journal-title":"Cell Growth Differ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.ATV.0000105902.89459.09","article-title":"Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels","volume":"24","author":"Delafontaine","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-0-387-89520-8_3","article-title":"Targeting TNF for Treatment of Cancer and Autoimmunity","volume":"647","author":"Sethi","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-\u03baB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell Mol. Life Sci."},{"key":"ref_11","first-page":"1267","article-title":"Mechanism and Function of Angiogenin in Hematopoietic Malignancy","volume":"31","author":"Goncalves","year":"2015","journal-title":"Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao"},{"key":"ref_12","first-page":"1","article-title":"The diverse roles of the TNF axis in cancer progression and metastasis","volume":"11","author":"Ham","year":"2016","journal-title":"Trends Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12032-017-1054-7","article-title":"Progranulin and its biological effects in cancer","volume":"34","author":"Gerton","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e12390","DOI":"10.1111\/cpr.12390","article-title":"IGF-1 promotes angiogenesis in endothelial cells\/adipose-derived stem cells co-culture system with activation of PI3K\/Akt signal pathway","volume":"50","author":"Lin","year":"2017","journal-title":"Cell Prolif."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2016.10.005","article-title":"Tumor necrosis factor \u03b1 in the onset and progression of leukemia","volume":"45","author":"Zhou","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1984718","DOI":"10.1155\/2018\/1984718","article-title":"The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis","volume":"2018","author":"Yu","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bauvois, B., and Susin, S.A. (2018). Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?. Cancers, 10.","DOI":"10.3390\/cancers10090336"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Do, H.T.T., Lee, C.H., and Cho, J. (2020). Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers, 12.","DOI":"10.3390\/cancers12020287"},{"key":"ref_19","first-page":"8809","article-title":"Role of midkine-progranulin interaction during angiogenesis of hepatocellular carcinoma","volume":"8","author":"Huang","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41389-021-00335-w","article-title":"Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: Opportunities and challenges","volume":"10","author":"Zhu","year":"2021","journal-title":"Oncogenesis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JME-14-0215","article-title":"Endothelial cells and the IGF system","volume":"54","author":"Bach","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nigro, E., Mallardo, M., Polito, R., Scial\u00f2, F., Bianco, A., and Daniele, A. (2021). Adiponectin and Leptin Exert Antagonizing Effects on HUVEC Tube Formation and Migration Modulating the Expression of CXCL1, VEGF, MMP-2 and MMP-9. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147516"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2141.2000.01864.x","article-title":"Current status of antiangiogenic factors","volume":"109","author":"Talks","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-6147(00)01676-X","article-title":"FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition","volume":"22","author":"Cross","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.onc.1205045","article-title":"Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis","volume":"21","author":"Pozzi","year":"2002","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, M., Qiu, L., Zhang, Y., Xu, D., Zheng, J.C., and Jiang, L. (2017). CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-08840-y"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Akwii, R.G., Sajib, M.S., Zahra, F.T., and Mikelis, C.M. (2019). Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology. Cells, 8.","DOI":"10.3390\/cells8050471"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/0008-5472.CAN-08-0540","article-title":"Neutrophil gelatinase-associated lipocalin: A novel suppressor of invasion and angiogenesis in pancreatic cancer","volume":"68","author":"Tong","year":"2008","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1002\/cncr.25803","article-title":"Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells","volume":"117","author":"Tong","year":"2011","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.12167","article-title":"ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer","volume":"6","author":"Guo","year":"2016","journal-title":"Theranostics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s11033-020-05261-5","article-title":"Implication and role of neutrophil gelatinase-associated lipocalin in cancer: Lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types","volume":"47","author":"Rahimi","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28823","DOI":"10.1074\/jbc.272.46.28823","article-title":"Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B\/type IV collagenase (MMP-9)","volume":"272","author":"Patterson","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1083\/jcb.152.6.1247","article-title":"Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation","volume":"152","author":"Troyanovsky","year":"2001","journal-title":"J. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: Regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00726-010-0689-x","article-title":"Physiology and pathophysiology of matrix metalloproteases","volume":"41","author":"Klein","year":"2011","journal-title":"Amino Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.anndiagpath.2007.08.002","article-title":"Pathology of chronic lymphocytic leukemia: An update","volume":"11","author":"Inamdar","year":"2007","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.13055\/ojhmt_3_S1_03.120221","article-title":"Cell Trafficking in Chronic Lymphocytic Leukemia","volume":"3","author":"Davids","year":"2012","journal-title":"Open J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tannoury, M., Garnier, D., Susin, S.A., and Bauvois, B. (2022). Current Status of Novel Agents for the Treatment of B Cell Malignancies: What\u2019s Coming Next?. Cancers, 14.","DOI":"10.3390\/cancers14246026"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wright, S.C.E., Vasilevski, N., Serra, V., Rodon, J., and Eichhorn, P.J.A. (2021). Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 13.","DOI":"10.3390\/cancers13071538"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: Lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114009","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_45","first-page":"9","article-title":"PI3K inhibitors in chronic lymphocytic leukemia: Where do we go from here?","volume":"108","author":"Brown","year":"2023","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/cncr.22303","article-title":"Role of angiogenesis in chronic lymphocytic leukemia","volume":"107","author":"Smolej","year":"2006","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1746-1596-3-16","article-title":"Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence","volume":"3","author":"Frater","year":"2008","journal-title":"Diagn. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/leu.2008.381","article-title":"Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon?","volume":"23","author":"Ribatti","year":"2009","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/scd.2004.13.484","article-title":"Hematopoietic cancer and angiogenesis","volume":"13","author":"Ribatti","year":"2004","journal-title":"Stem Cells Dev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2009.12.044","article-title":"Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain","volume":"17","author":"Terol","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.biochi.2024.07.006","article-title":"CD38\/NAD(+) glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies","volume":"227","author":"Bauvois","year":"2024","journal-title":"Biochimie"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12307-012-0106-y","article-title":"Role of bone marrow-derived cells in angiogenesis: Focus on macrophages and pericytes","volume":"5","author":"Ding","year":"2012","journal-title":"Cancer Microenviron."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10456-017-9541-1","article-title":"The role of vasculature in bone development, regeneration and proper systemic functioning","volume":"20","author":"Filipowska","year":"2017","journal-title":"Angiogenesis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41590-020-0635-3","article-title":"Lymph node stromal cells: Cartographers of the immune system","volume":"21","author":"Krishnamurty","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","article-title":"Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2401825","article-title":"Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia","volume":"14","author":"Kini","year":"2000","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2002-01-0084","article-title":"Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia","volume":"100","author":"Molica","year":"2002","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0609.2003.00110.x","article-title":"Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia","volume":"71","author":"Molica","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.leu.2402970","article-title":"Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia","volume":"17","author":"Ribatti","year":"2003","journal-title":"Leukemia"},{"key":"ref_60","first-page":"263","article-title":"Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia","volume":"26","author":"Wolowiec","year":"2004","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"ref_61","first-page":"50","article-title":"Angiogenesis in the bone marrow of patients with chronic lymphocytic leukaemia","volume":"43","author":"Smolej","year":"2007","journal-title":"Ceskoslovenska Patol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood.V96.9.3181","article-title":"In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells","volume":"96","author":"Chen","year":"2000","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Levidou, G., Sachanas, S., Pangalis, G.A., Kalpadakis, C., Yiakoumis, X., Moschogiannis, M., Sepsa, A., Lakiotaki, E., Milionis, V., and Kyrtsonis, M.C. (2014). Immunohistochemical analysis of IL-6, IL-8\/CXCR2 axis, \u2009Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: Correlation between microvascular characteristics and prognostic significance. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/251479"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.seminoncol.2006.01.008","article-title":"The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia","volume":"33","author":"Shanafelt","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V97.8.2529","article-title":"Angiogenesis is increased in B-cell chronic lymphocytic leukemia","volume":"97","author":"Peterson","year":"2001","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/152581603321210091","article-title":"Angiogenesis and anti-angiogenesis in hematological malignancies","volume":"12","author":"Ribatti","year":"2003","journal-title":"J. Hematother. Stem Cell Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2008.255","article-title":"Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors","volume":"23","author":"Negaard","year":"2009","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.leukres.2006.11.024","article-title":"Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an \u201cangiogenic switch\u201d","volume":"31","author":"Kay","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.leukres.2008.03.003","article-title":"Bone marrow fibroblasts induce expression of PI3K\/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells","volume":"32","author":"Edelmann","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbrc.2019.09.127","article-title":"Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells","volume":"520","author":"Samaniego","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Dubois, N., Crompot, E., Meuleman, N., Bron, D., Lagneaux, L., and Stamatopoulos, B. (2020). Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01422"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.humpath.2011.02.027","article-title":"Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: Role of signal transducer and activator of transcription 3","volume":"42","author":"Badoux","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3109\/10428194.2012.672735","article-title":"CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro","volume":"53","author":"Burgess","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.leukres.2009.06.023","article-title":"Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF","volume":"34","author":"Maffei","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41416-021-01611-7","article-title":"CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles","volume":"125","author":"Aitamer","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.critrevonc.2014.10.007","article-title":"Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?","volume":"93","author":"Gehrke","year":"2015","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.bjc.6600022","article-title":"Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia","volume":"86","author":"Molica","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1034\/j.1600-0609.2003.00064.x","article-title":"Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia","volume":"70","author":"Molica","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2141.2004.04877.x","article-title":"The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia","volume":"125","author":"Kamiguti","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.leukres.2004.03.010","article-title":"Relationship between cell surface expression of CD38 and of vascular endothelial growth factor in B-cell chronic lymphocytic leukemia","volume":"28","author":"McCabe","year":"2004","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/10245330701340759","article-title":"Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"12","author":"Aref","year":"2007","journal-title":"Hematology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.leukres.2007.03.009","article-title":"Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia","volume":"31","author":"Molica","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.leukres.2007.09.002","article-title":"Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis","volume":"32","author":"Martinelli","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2404363","article-title":"Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status","volume":"20","author":"Thomale","year":"2006","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4149\/neo_2014_071","article-title":"Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia","volume":"61","author":"Vrbacky","year":"2014","journal-title":"Neoplasma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1038\/s41375-021-01376-1","article-title":"CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness","volume":"35","author":"Lewis","year":"2021","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0609.2004.00269.x","article-title":"Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression","volume":"73","author":"Molica","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V87.3.1056.bloodjournal8731056","article-title":"Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine","volume":"87","author":"Menzel","year":"1996","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.leu.2402012","article-title":"FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias","volume":"15","author":"Mayer","year":"2001","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2402467","article-title":"B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules","volume":"16","author":"Kay","year":"2002","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.leukres.2007.06.007","article-title":"Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen","volume":"32","author":"Hus","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bauvois, B., Pramil, E., Jondreville, L., Chapiro, E., Quiney, C., Maloum, K., Susin, S.A., and Nguyen-Khac, F. (2020). Relation of Neutrophil Gelatinase-Associated Lipocalin Overexpression to the Resistance to Apoptosis of Tumor B Cells in Chronic Lymphocytic Leukemia. Cancers, 12.","DOI":"10.3390\/cancers12082124"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2005.05579.x","article-title":"Autocrine\/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia","volume":"130","author":"Schillaci","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Schulze-Edinghausen, L., D\u00fcrr, C., \u00d6zt\u00fcrk, S., Zucknick, M., Benner, A., Kalter, V., Ohl, S., Close, V., Wuchter, P., and Stilgenbauer, S. (2019). Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11060822"},{"key":"ref_95","unstructured":"Sanc\u00e9au, J., and Bauvois, B. (2024). Angiogenin expression in chronic lymphocytic leukemia cells and inhibition by interferons type I and II. Pers. Commun. Unpubl. Work."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_5-4","article-title":"Angiogenic growth factors: Autocrine and paracrine regulation of survival in hematologic malignancies","volume":"6","author":"Gabrilove","year":"2001","journal-title":"Oncologist"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2017.177808","article-title":"Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin","volume":"103","author":"Hanna","year":"2018","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0145-2126(00)00139-9","article-title":"Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)","volume":"25","author":"Aguayo","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/0962935031000134888","article-title":"Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia","volume":"12","author":"Blonski","year":"2003","journal-title":"Mediat. Inflamm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1532\/IJH97.NA0411","article-title":"Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases","volume":"83","author":"Avcu","year":"2006","journal-title":"Int. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12185-008-0165-5","article-title":"Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia","volume":"88","author":"Molica","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"287974","DOI":"10.1155\/2009\/287974","article-title":"Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?","volume":"2009","author":"Molica","year":"2009","journal-title":"Adv. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7123\/01.EJH.0000418697.30240.35","article-title":"Role of adiponectin in chronic lymphocytic leukemia","volume":"37","author":"Akl","year":"2012","journal-title":"Egypt. J. Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/172460080101600102","article-title":"Circulating angiogenesis regulators in cancer patients","volume":"16","author":"Kuroi","year":"2001","journal-title":"Int. J. Biol. Markers"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/15233","article-title":"CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia","volume":"5","author":"Mateo","year":"1999","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2141.2009.07811.x","article-title":"Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia","volume":"146","author":"Shanafelt","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_107","first-page":"29","article-title":"Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia","volume":"8","author":"Baban","year":"1996","journal-title":"Int. J. Oncol."},{"key":"ref_108","first-page":"1106","article-title":"Vascular endothelial growth factor isoforms 121 and 165 are expressed on B-chronic lymphocytic leukemia cells","volume":"85","author":"Molica","year":"2000","journal-title":"Haematologica"},{"key":"ref_109","first-page":"57","article-title":"Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders","volume":"48","author":"Smolej","year":"2005","journal-title":"Acta Medica"},{"key":"ref_110","first-page":"1171","article-title":"Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment","volume":"53","author":"Smolej","year":"2007","journal-title":"Vnitr. Lek."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/10428190109099320","article-title":"Angiogenesis in B-cell chronic lymphocytic leukemia: Methods of study, clinical significance and prognostic implications","volume":"42","author":"Molica","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood.V96.2.768.014k23_768_770","article-title":"Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia","volume":"96","author":"Aguayo","year":"2000","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0145-2126(00)00161-2","article-title":"Angiogenesis and leukemia","volume":"25","author":"Keyhani","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2119\/molmed.2010.00210","article-title":"Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells","volume":"17","author":"Gehrke","year":"2011","journal-title":"Mol. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Wang, X., Bove, A.M., Simone, G., and Ma, B. (2020). Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.599281"},{"key":"ref_116","first-page":"795","article-title":"High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia","volume":"7","author":"Ferrajoli","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2003-08-2763","article-title":"VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.leu.2403837","article-title":"VEGF-induced survival of chronic lymphocytic leukemia is independent of Bcl-2 phosphorylation","volume":"19","author":"Wang","year":"2005","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.leu.2403667","article-title":"VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance","volume":"19","author":"Lee","year":"2005","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.leu.2404587","article-title":"Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin","volume":"21","author":"Pepper","year":"2007","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo","volume":"16","author":"Paesler","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_122","first-page":"846","article-title":"VEGF\/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration","volume":"115","author":"Eroles","year":"2009","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2019000019","article-title":"alpha4beta1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling","volume":"3","author":"Bailon","year":"2019","journal-title":"Blood Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.leu.2404650","article-title":"Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: Association with clinical outcome and immunoglobulin heavy-chain mutational status","volume":"21","author":"Maffei","year":"2007","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1179\/102453309X12583347113898","article-title":"Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features","volume":"15","author":"Vrbacky","year":"2010","journal-title":"Hematology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2448","article-title":"Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement","volume":"36","author":"Maffei","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/sj.leu.2402472","article-title":"Production of matrix metalloproteinase-9 in early stage B-CLL: Suppression by interferons","volume":"16","author":"Bauvois","year":"2002","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1182\/blood-2006-03-007294","article-title":"MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration","volume":"108","author":"Samaniego","year":"2006","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2007-08-109249","article-title":"Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B\/MMP-9 in chronic leukemic but not in normal B cells","volume":"112","author":"Opdenakker","year":"2008","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"27601","DOI":"10.1074\/jbc.M112.354670","article-title":"A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds alpha4beta1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells","volume":"287","author":"Bailon","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2001.02731.x","article-title":"Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia","volume":"113","author":"Bairey","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_132","first-page":"77","article-title":"Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells","volume":"9","author":"Allouche","year":"1995","journal-title":"Leukemia"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V76.2.393.bloodjournal762393","article-title":"Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease","volume":"76","author":"Foa","year":"1990","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","article-title":"The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia","volume":"100","author":"Ferrajoli","year":"2002","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0959-8049(94)90169-4","article-title":"Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia","volume":"30","author":"Adami","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1172\/JCI115769","article-title":"High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia","volume":"89","author":"Digel","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(88)91782-5","article-title":"Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies","volume":"1","author":"Cordingley","year":"1988","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V80.5.1299.1299","article-title":"Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells","volume":"80","author":"Rensink","year":"1992","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V73.5.1242.1242","article-title":"Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia","volume":"73","author":"Digel","year":"1989","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00109-013-1081-6","article-title":"RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow","volume":"92","author":"Xu","year":"2014","journal-title":"J. Mol. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/icb.1997.17","article-title":"Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2","volume":"75","author":"Tangye","year":"1997","journal-title":"Immunol. Cell Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood-2008-02-137802","article-title":"CLL and activated NF-kappaB: Living partnership","volume":"111","author":"Hertlein","year":"2008","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.29409\/ijcmg.v15i1.329","article-title":"Evaluation of Serum Level of CXCL12 in Correlation with Several Clinical and Hematological Parameters in Patients with Chronic Lymphocytic leukemia","volume":"15","author":"Abdulrazzaq","year":"2022","journal-title":"Iraqi J. Cancer Med. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-011-1218-z","article-title":"Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma","volume":"90","author":"Plander","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","article-title":"Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1)","volume":"13","author":"Failenschmid","year":"1999","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.26607","article-title":"Role of chemokines and their receptors in chronic lymphocytic leukemia: Function in microenvironment and targeted therapy","volume":"15","author":"Han","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Redondo-Mu\u00f1oz, J., Garc\u00eda-Pardo, A., and Teixid\u00f3, J. (2019). Molecular Players in Hematologic Tumor Cell Trafficking. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00156"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","article-title":"Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells","volume":"106","author":"Burger","year":"2005","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2010-04-282400","article-title":"Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib","volume":"117","author":"Messmer","year":"2011","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","article-title":"Isoform-selective phosphoinositide 3\u2032-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: A novel therapeutic approach","volume":"113","author":"Niedermeier","year":"2009","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2010.36","article-title":"CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells","volume":"24","author":"Vaisitti","year":"2010","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2007-06-094029","article-title":"CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential","volume":"110","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1182\/blood-2004-10-4054","article-title":"CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium","volume":"105","author":"Till","year":"2005","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"35123","DOI":"10.18632\/oncotarget.26212","article-title":"CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton\u2019s tyrosine kinase","volume":"9","author":"Montresor","year":"2018","journal-title":"Oncotarget"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3324\/haematol.2010.031377","article-title":"Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: A dominant role of CCL2","volume":"96","author":"Schulz","year":"2011","journal-title":"Haematologica"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3109\/10428194.2012.688966","article-title":"CCL2 in chronic lymphocytic leukemia: A macro in microenvironment?","volume":"53","author":"Gandhi","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4274\/tjh.2016.0075","article-title":"Evaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia","volume":"33","author":"Ayer","year":"2016","journal-title":"Turk. J. Haematol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0609.2005.00553.x","article-title":"Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression","volume":"76","author":"Molica","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood-2013-02-484386","article-title":"Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia","volume":"122","author":"Yaktapour","year":"2013","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/leu.2015.305","article-title":"Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo","volume":"30","author":"Hanna","year":"2016","journal-title":"Leukemia"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.exphem.2013.10.007","article-title":"Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia","volume":"42","author":"Maffei","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"G\u00f6bel, M., Eisele, L., M\u00f6llmann, M., H\u00fcttmann, A., Johansson, P., Scholtysik, R., Bergmann, M., Busch, R., D\u00f6hner, H., and Hallek, M. (2013). Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072107"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.biochi.2012.01.001","article-title":"Metabolic effects of anti-angiogenic therapy in tumors","volume":"94","author":"Zulato","year":"2012","journal-title":"Biochimie"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00005-012-0197-7","article-title":"Serum tumor necrosis factor-\u03b1 and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status","volume":"60","author":"Wyka","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2011.12","article-title":"IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells","volume":"25","author":"Coscia","year":"2011","journal-title":"Leukemia"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1541-7786.MCR-10-0559","article-title":"STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells","volume":"9","author":"Liu","year":"2011","journal-title":"Mol. Cancer Res. MCR"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55133\/eji.280312","article-title":"CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients","volume":"28","author":"Aly","year":"2021","journal-title":"Egypt. J. Immunol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2009-05-219634","article-title":"In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia","volume":"114","author":"Calissano","year":"2009","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","article-title":"ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation","volume":"118","author":"Calpe","year":"2011","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/hon.3144","article-title":"Functional consequences of inhibition of Bruton\u2019s tyrosine kinase by ibrutinib in chronic lymphocytic leukemia","volume":"41","author":"Chen","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_175","first-page":"129","article-title":"The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer","volume":"1826","author":"Chakraborty","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1074\/jbc.M115.685644","article-title":"Biochemical and Structural Characterization of the Interaction between the Siderocalin NGAL\/LCN2 (Neutrophil Gelatinase-associated Lipocalin\/Lipocalin 2) and the N-terminal Domain of Its Endocytic Receptor SLC22A17","volume":"291","author":"Weinhaupl","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Bauvois, B., Chapiro, E., Quiney, C., Maloum, K., Susin, S.A., and Nguyen-Khac, F. (2023). The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092335"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/10408363.2024.2306804","article-title":"Challenges of insulin-like growth factor-1 testing","volume":"61","author":"Huang","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/1078-0432.CCR-11-0998","article-title":"The insulin receptor\/insulin-like growth factor receptor family as a therapeutic target in oncology","volume":"18","author":"Pollak","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/abbs\/gmv131","article-title":"Three decades of research on angiogenin: A review and perspective","volume":"48","author":"Sheng","year":"2016","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cell.2017.10.005","article-title":"Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin","volume":"171","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5604\/17322693.1038349","article-title":"Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells","volume":"67","author":"Bogusz","year":"2013","journal-title":"Postep. Hig. Med. Dosw. (Online)"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3109\/10428194.2010.524327","article-title":"Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia","volume":"51","author":"Shanafelt","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/cncr.28910","article-title":"FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia","volume":"120","author":"Jain","year":"2014","journal-title":"Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"78269","DOI":"10.18632\/oncotarget.13412","article-title":"A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia","volume":"7","author":"Kay","year":"2016","journal-title":"Oncotarget"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Finlayson, M. (2015). Modulation of CD44 Activity by A6-Peptide. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00135"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"15340","DOI":"10.1074\/jbc.M114.559187","article-title":"A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells","volume":"289","author":"Albar","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1073\/pnas.1221841110","article-title":"Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: Therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/13543776.2014.915942","article-title":"Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: Evaluation of WO2013063498","volume":"24","author":"Calapai","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-12-544569","article-title":"Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia","volume":"123","author":"Walsby","year":"2014","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1182\/blood-2012-08-447664","article-title":"Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment","volume":"121","author":"Schulz","year":"2013","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2017-11-817296","article-title":"Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide","volume":"131","author":"Takahashi","year":"2018","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/bloodadvances.2019031336","article-title":"Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL","volume":"3","author":"Strati","year":"2019","journal-title":"Blood Adv."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0145-2126(89)90004-0","article-title":"Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and beta","volume":"13","author":"Moberts","year":"1989","journal-title":"Leuk. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V108.11.2841.2841","article-title":"A Phase II Study of the TNF-\u03b1 Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL\/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities","volume":"108","author":"Lin","year":"2006","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/leu.2008.385","article-title":"A phase I\/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"23","author":"Woyach","year":"2009","journal-title":"Leukemia"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_200","first-page":"1996","article-title":"Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine\/Rituximab in Patients with Chronic Lymphocytic Leukemia","volume":"124","author":"Steurer","year":"2014","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.2010.08316.x","article-title":"The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia\u2014CXCR4 antagonists as potential adjuvants for monoclonal antibodies","volume":"151","author":"Buchner","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3324\/haematol.2011.052779","article-title":"AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: Pre-clinical evidence for its association with chronic lymphocytic leukemia treatments","volume":"97","author":"Stamatopoulos","year":"2012","journal-title":"Haematologica"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1182\/blood.V124.21.5658.5658","article-title":"Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)","volume":"124","author":"Brander","year":"2014","journal-title":"Blood"},{"key":"ref_205","first-page":"2450","article-title":"Preliminary results from a phase I\/II dose escalation study to determine the maximum tolerated from a phase I\/II dose escalation study to determine the maximum tolerated chronic lymphocytic leukemia","volume":"95","author":"Andritsos","year":"2010","journal-title":"Haematologica"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1080\/10428194.2019.1643463","article-title":"A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia","volume":"60","author":"Andritsos","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.18632\/oncotarget.6465","article-title":"Ulocuplumab (BMS-936564\/MDX1338): A fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"16024","DOI":"10.1038\/mto.2016.24","article-title":"Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research","volume":"3","author":"Inoo","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-Angiogenics: Current Situation and Future Perspectives","volume":"41","author":"Zirlik","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568009619666191114110359","article-title":"Anti-VEGF\/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1\/PD-L1 Inhibitors in Clinic","volume":"20","author":"Gao","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc2228","article-title":"Emerging roles of proteases in tumour suppression","volume":"7","author":"Matrisian","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.mam.2008.05.002","article-title":"Progress in matrix metalloproteinase research","volume":"29","author":"Murphy","year":"2008","journal-title":"Mol. Asp. Med."},{"key":"ref_216","first-page":"29","article-title":"New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression","volume":"1825","author":"Bauvois","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1369\/00221554211035192","article-title":"Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment","volume":"69","author":"Novak","year":"2021","journal-title":"J. Histochem. Cytochem."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Goto, N., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2022). Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105535"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"Brandstadter","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_221","first-page":"189","article-title":"Natalizumab in Crohn\u2019s disease: Past and future areas of applicability","volume":"26","author":"Armuzzi","year":"2013","journal-title":"Ann. Gastroenterol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2011.08794.x","article-title":"Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin \u03b1-4-\u03b2-1 (VLA-4) with natalizumab can overcome this resistance","volume":"155","author":"Mraz","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2011.08864.x","article-title":"The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications","volume":"155","author":"Podar","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14737140.2.3.277","article-title":"TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies","volume":"2","author":"Tsimberidou","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_226","first-page":"5251","article-title":"Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy","volume":"14","author":"Liu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/10428190902777467","article-title":"N9986: A phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia","volume":"50","author":"Kay","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1517\/14656566.2011.635644","article-title":"Treating chronic lymphocytic leukemia with thalidomide and lenalidomide","volume":"12","author":"Giannopoulos","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11899-012-0146-x","article-title":"Lenalidomide alone and in combination for chronic lymphocytic leukemia","volume":"8","author":"Chen","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1038\/bcj.2016.9","article-title":"Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial","volume":"6","author":"Wendtner","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Zaritskey","year":"2017","journal-title":"Lancet. Haematol."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Rodr\u00edguez, A.P., Payer, A.R., Acebes-Huerta, A., Huergo-Zapico, L., Villa-Alvarez, M., Gonzalez-Garc\u00eda, E., and Gonzalez, S. (2013). Lenalidomide and chronic lymphocytic leukemia. BioMed Res. Int., 2013.","DOI":"10.1155\/2013\/932010"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments: Clinical and therapeutic implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/13543784.2011.546343","article-title":"Lenalidomide in the treatment of chronic lymphocytic leukemia","volume":"20","author":"Gentile","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/13543784.2017.1313230","article-title":"Lenalidomide in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Itchaki","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3324\/haematol.2019.230805","article-title":"Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: Final results of the NCRI CLL210 trial","volume":"105","author":"Pettitt","year":"2020","journal-title":"Haematologica"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-002-0479-6","article-title":"Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies","volume":"50","author":"Tsimberidou","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0093-7754(03)00239-2","article-title":"Rituximab in B-cell chronic lymphocytic leukemia","volume":"30","author":"Lin","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","article-title":"Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment","volume":"1863","author":"Burger","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1084\/jem.20052144","article-title":"A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development","volume":"203","author":"Burns","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","article-title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment","volume":"149","author":"Bao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1210\/en.2011-0231","article-title":"Minireview: IGF, Insulin, and Cancer","volume":"152","author":"Gallagher","year":"2011","journal-title":"Endocrinology"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Lin, S.L., Lin, C.Y., Lee, W., Teng, C.F., Shyu, W.C., and Jeng, L.B. (2022). Mini Review: Molecular Interpretation of the IGF\/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911781"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"29501","DOI":"10.18632\/oncotarget.15704","article-title":"Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy","volume":"8","author":"Qu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Ianza, A., Sirico, M., Bernocchi, O., and Generali, D. (2021). Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.641449"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5732\/cjc.012.10263","article-title":"IGF-1R as an anti-cancer target--trials and tribulations","volume":"32","author":"Chen","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_249","first-page":"1303","article-title":"Molecular targeted therapies for cancer: Sorafenib mono-therapy and its combination with other therapies (review)","volume":"27","author":"Ibrahim","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: Theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"174021","DOI":"10.1016\/j.ejphar.2021.174021","article-title":"Angiopoietin inhibitors: A review on targeting tumor angiogenesis","volume":"899","author":"Parmar","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Qi, S., Deng, S., Lian, Z., and Yu, K. (2022). Novel Drugs with High Efficacy against Tumor Angiogenesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136934"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"154677","DOI":"10.1016\/j.prp.2023.154677","article-title":"A comprehensive insight into the role of molecular pathways affected by the Angiopoietin and Tie system involved in hematological malignancies\u2019 pathogenesis","volume":"248","author":"Zhang","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/10799893.2023.2204983","article-title":"An overview of the molecular and clinical significance of the angiopoietin system in leukemia","volume":"43","author":"Moonesi","year":"2023","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.4155\/fmc-2018-0103","article-title":"Recent developments and advances of FGFR as a potential target in cancer","volume":"10","author":"Xue","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41467-023-35969-4","article-title":"Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"14","author":"Coombes","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"10066","DOI":"10.1073\/pnas.152342999","article-title":"A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity","volume":"99","author":"Kao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e30654","DOI":"10.1016\/j.heliyon.2024.e30654","article-title":"Research progress on the structure, function, and use of angiogenin in malignant tumours","volume":"10","author":"Mao","year":"2024","journal-title":"Heliyon"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Crescenzi, E., Leonardi, A., and Pacifico, F. (2021). NGAL as a Potential Target in Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212333"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/0006-291X(87)90937-5","article-title":"Production of IGF-binding proteins by vascular endothelial cells","volume":"148","author":"Bar","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1172\/JCI116450","article-title":"Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis","volume":"91","author":"Shweiki","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.onc.1208223","article-title":"Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis","volume":"24","author":"Kishimoto","year":"2005","journal-title":"Oncogene"},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Toh, H., Cao, M., Daniels, E., and Bateman, A. (2013). Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: A novel mouse model. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064989"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.ATV.20.2.410","article-title":"Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha","volume":"20","author":"Imaizumi","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ccell.2015.05.002","article-title":"CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance","volume":"27","author":"Pitt","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00018-019-03031-6","article-title":"Role of bone marrow adipocytes in leukemia and chemotherapy challenges","volume":"76","author":"Samimi","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","article-title":"Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment","volume":"129","author":"Shafat","year":"2017","journal-title":"Blood"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2017004960","article-title":"Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia","volume":"1","author":"Cahu","year":"2017","journal-title":"Blood Adv."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","article-title":"Novel therapies targeting the myeloma cell and its bone marrow microenvironment","volume":"28","author":"Hideshima","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_273","first-page":"146","article-title":"Angiogenesis and endothelial cells in blood neoplasms","volume":"63","author":"Poreba","year":"2006","journal-title":"Prz. Lek."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0171-2985(99)80038-2","article-title":"Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals","volume":"200","author":"Schuler","year":"1999","journal-title":"Immunobiology"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000087886","article-title":"Autocrine expression of platelet-derived growth factor B in B cell chronic lymphocytic leukemia","volume":"114","author":"Ho","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0106wik\u0142a, A., M\u0105czy\u0144ski, M., and Regiec, A. (2021). FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review. Cancers, 14.","DOI":"10.3390\/cancers14010087"},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Lu, R.M., Hwang, Y.C., Liu, I.J., Lee, C.C., Tsai, H.Z., Li, H.J., and Wu, H.C. (2020). Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-019-0592-z"},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Chen, Y.J., Abila, B., and Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15.","DOI":"10.3390\/cancers15030663"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1080\/10428194.2017.1285027","article-title":"Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia","volume":"58","author":"Vojdeman","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/2040620712458949","article-title":"Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: A history and discussion of future rational use","volume":"3","author":"Warner","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","article-title":"Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia","volume":"103","author":"Rawstron","year":"2004","journal-title":"Blood"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","article-title":"Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia","volume":"96","author":"Bowen","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3747\/co.2007.118","article-title":"Alemtuzumab in chronic lymphocytic leukemia","volume":"14","author":"Fraser","year":"2007","journal-title":"Curr. Oncol."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Pula, B., Golos, A., Gorniak, P., and Jamroziak, K. (2019). Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11121834"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/152581602753448522","article-title":"A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies","volume":"11","author":"Rajkumar","year":"2002","journal-title":"J. Hematother. Stem Cell Res."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2006.11.006","article-title":"Angiogenesis and antiangiogenic therapy in hematologic malignancies","volume":"62","author":"Dong","year":"2007","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2040-2384-2-10","article-title":"Clinical trials with anti-angiogenic agents in hematological malignancies","volume":"2","author":"Medinger","year":"2010","journal-title":"J. Angiogenesis Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2011.1.1","article-title":"Angiogenesis: A target in solid tumors, also in leukemia?","volume":"2011","author":"Schmidt","year":"2011","journal-title":"Hematology"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10456-020-09729-7","article-title":"B-cell non-Hodgkin lymphoma: Importance of angiogenesis and antiangiogenic therapy","volume":"23","author":"Jiang","year":"2020","journal-title":"Angiogenesis"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2174\/1381612043452587","article-title":"Antiangiogenic therapy in hematologic malignancies","volume":"10","author":"Moehler","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.2174\/092986712803341548","article-title":"State of the art of the therapeutic perspective of sorafenib against hematological malignancies","volume":"19","author":"Zauli","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/cncr.30585","article-title":"Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2010.09.009","article-title":"VEGF targeted therapy in acute myeloid leukemia","volume":"80","author":"Aranda","year":"2011","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2012-04-420596","article-title":"Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: A randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)","volume":"120","author":"Ossenkoppele","year":"2012","journal-title":"Blood"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: A report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:52Z","timestamp":1760115352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/1\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":297,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17010072"],"URL":"https:\/\/doi.org\/10.3390\/cancers17010072","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}